CNCE · Concert Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.0K | $21.0K | $0 | - | $543.0K | $32.02M | $5.0K | - | $1.50M | $6.39M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $24.36M | $20.86M | $30.49M | - | $21.88M | $20.18M | $18.50M | - | $16.35M | $14.79M |
| SG&A | $5.25M | $4.85M | $5.54M | - | $5.46M | $5.61M | $5.49M | - | $4.51M | $4.73M |
| Total Operating Expenses | $29.61M | $25.70M | $36.03M | - | $27.34M | $25.80M | $23.98M | - | $20.86M | $19.52M |
| D&A | - | - | $321.0K | - | - | - | $392.0K | - | - | - |
| Operating Income | ($29.61M) | ($25.68M) | ($36.03M) | - | ($26.80M) | $6.22M | ($23.98M) | - | ($19.36M) | ($13.13M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | $0 | $0 | - | - | $0 | ($85.0K) |
| Net Income | ($28.90M) | ($23.55M) | ($37.73M) | - | ($26.68M) | $5.42M | ($22.67M) | - | ($18.91M) | ($12.99M) |
| EPS - Basic | ($0.58) | ($0.59) | ($1.03) | - | ($0.78) | ($0.41) | - | - | - | - |
| EPS - Diluted | ($0.58) | ($0.59) | ($1.03) | - | ($0.78) | ($0.41) | - | - | - | - |
Balance Sheet
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $95.19M | $139.25M | $59.36M | $141.64M | $103.66M | $122.40M | $89.77M | $77.20M | $33.67M | $27.09M |
| Accounts Receivable | $1.44M | $1.07M | $744.0K | $218.0K | $476.0K | $240.0K | $79.0K | $686.0K | $130.0K | $50.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.75M | $1.37M | $2.75M | $2.61M | $584.0K | $0 | $508.0K | $230.0K | $265.0K | $352.0K |
| Current Assets | $157.20M | $162.12M | $114.77M | $150.33M | $112.91M | $132.98M | $123.86M | $142.72M | $136.37M | $154.59M |
| Total Assets | $171.13M | $176.39M | $129.41M | $165.32M | $128.21M | $148.71M | $139.99M | $159.26M | $153.37M | $172.00M |
| Current Liabilities | $17.40M | $16.16M | $15.08M | $16.12M | $12.02M | $8.67M | $8.30M | $10.18M | $7.37M | $9.62M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $37.86M | $48.60M | $52.84M | $53.09M | $29.05M | $25.99M | $25.95M | $28.10M | $25.43M | $27.91M |
| Stockholders' Equity | $133.27M | $127.79M | $76.57M | $112.22M | $99.16M | $122.72M | $114.04M | $131.16M | $127.94M | $144.09M |
| Retained Earnings | ($440.05M) | ($411.27M) | ($387.23M) | ($349.50M) | ($313.37M) | ($286.69M) | ($292.12M) | ($269.45M) | - | ($228.15M) |
Cash Flow
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($32.32M) | - | - | - | ($20.71M) | - | - | - |
| Investing Cash Flow | - | - | ($49.95M) | - | - | - | $30.62M | - | - | - |
| Financing Cash Flow | - | - | $0 | - | - | - | $2.66M | - | - | - |
| CapEx | - | - | $92.0K | - | - | - | $92.0K | - | - | - |
| Free Cash Flow | - | - | ($32.42M) | - | - | - | ($20.81M) | - | - | - |
Ratios
| Metric | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -370075.0% | -122300.0% | - | - | -4934.6% | 19.4% | -479600.0% | - | -1289.8% | -205.6% |
| EBITDA margin | - | - | - | - | - | - | -471760.0% | - | - | - |
| Net margin | -361300.0% | -112133.3% | - | - | -4913.1% | 16.9% | -453380.0% | - | -1259.7% | -203.4% |
| Free cash flow margin | - | - | - | - | - | - | -416120.0% | - | - | - |
| FCF / Net income | - | - | 0.86 | - | - | - | 0.92 | - | - | - |
| R&D / Revenue | 304550.0% | 99309.5% | - | - | 4028.7% | 63.0% | 370000.0% | - | 1089.1% | 231.5% |
| SG&A / Revenue | 65625.0% | 23090.5% | - | - | 1005.9% | 17.5% | 109700.0% | - | 300.7% | 74.1% |
| Effective tax rate | - | - | - | - | - | 0.0% | - | - | - | - |
| Return on assets | -16.9% | -13.3% | -29.2% | - | -20.8% | 3.6% | -16.2% | - | -12.3% | -7.6% |
| Return on equity | -21.7% | -18.4% | -49.3% | - | -26.9% | 4.4% | -19.9% | - | -14.8% | -9.0% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 9.03 | 10.03 | 7.61 | 9.33 | 9.39 | 15.34 | 14.92 | 14.02 | 18.51 | 16.07 |
| Quick ratio | 9.03 | 10.03 | 7.61 | 9.33 | 9.39 | 15.34 | 14.92 | 14.02 | 18.51 | 16.07 |
| Cash ratio | 5.47 | 8.62 | 3.94 | 8.79 | 8.62 | 14.12 | 10.81 | 7.59 | 4.57 | 2.82 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.28 | 1.38 | 1.69 | 1.47 | 1.29 | 1.21 | 1.23 | 1.21 | 1.20 | 1.19 |
| Liabilities / Assets | 0.22 | 0.28 | 0.41 | 0.32 | 0.23 | 0.17 | 0.19 | 0.18 | 0.17 | 0.16 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.22 | 0.00 | - | 0.01 | 0.04 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 65700d | 18632d | - | - | 320d | 3d | 5767d | - | 32d | 3d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -98.5% | -99.9% | -100.0% | - | -63.8% | 401.3% | -28.6% | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | -84.4% | 1187.5% | - | - | -78.1% | 652.3% |
| Revenue CAGR (5y) | -85.9% | 7.0% | - | - | 83.6% | 239.5% | -38.3% | - | -2.6% | -34.6% |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -10.5% | - | -50.2% | - | -38.4% | - | -28.6% | - | -6.1% | 32.4% |
| Net income growth (YoY) | -8.3% | - | -66.4% | - | -41.1% | - | -10.7% | - | -10.0% | 30.4% |
| EPS growth (YoY) | 25.6% | -43.9% | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -55.8% | - | - | - | -15.9% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 34.4% | 4.1% | -32.9% | -14.4% | -22.5% | -14.8% | -26.2% | 29.3% | 7.3% | 7.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$32.58M totalOther Revenue$32.54M · 99.9%
License And Research And Development Revenue$39.0K · 0.1%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CONCERT PHARMACEUTICALS against the 5 most active filers in the same SIC group.